Australien - engelsk - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.69 mg - capsule, enteric - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); triethyl citrate; titanium dioxide; mannitol; hypromellose; gelatin; stearoyl macrogolglycerides; maize starch; polysorbate 80; purified talc; iron oxide yellow; sucrose; diacetylated monoglycerides; purified water; dimeticone 350; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory,drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 43.37 mg - capsule, enteric - excipient ingredients: maize starch; dimeticone 350; gelatin; purified water; hypromellose; sucrose; methacrylic acid - ethyl acrylate copolymer (1:1); titanium dioxide; polysorbate 80; triethyl citrate; purified talc; iron oxide yellow; diacetylated monoglycerides; mannitol; stearoyl macrogolglycerides; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory,drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

USA - engelsk - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - esomeprazole magnesium dihydrate (unii: 36h71644eq) (esomeprazole - unii:n3pa6559ft) - healing of erosive esophagitis esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. maintenance of healing of erosive esophagitis esomeprazole magnesium delayed-release capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. symptomatic gastroesophageal reflux disease esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults and children 1 year or older. esomeprazole magnesium delayed-release capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous

USA - engelsk - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - healing of erosive esophagitis esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. maintenance of healing of erosive esophagitis esomeprazole magnesium delayed-release capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. symptomatic gastroesophageal reflux disease esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults and children 1 year or older. esomeprazole magnesium delayed-release capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy

USA - engelsk - NLM (National Library of Medicine)

advanced rx pharmacy of tennessee, llc - esomeprazole magnesium dihydrate (unii: 36h71644eq) (esomeprazole - unii:n3pa6559ft) - 1 indications and usage 1.1 treatment of gastroesophageal reflux disease (gerd) healing of erosive esophagitis esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. maintenance of healing of erosive esophagitis esomeprazole magnesium delayed-release capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. symptomatic gastroesophageal reflux disease esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults and children 1 year or older. 1.2 risk reduction of nsaid-associated gastric ulcer esomepra

USA - engelsk - NLM (National Library of Medicine)

advanced rx pharmacy of tennessee, llc - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - 1.1 healing of erosive esophagitis (ee) adults esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed ee in adults. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. pediatric patients 12 years to 17 years of age esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) for the healing of ee in pediatric patients 12 years to 17 years of age. 1.2 maintenance of healing of ee esomeprazole magnesium delayed-release capsules are indicated for the maintenance of healing of ee in adults. controlled studies do not extend beyond 6 months. 1.3 treatment of symptomatic gerd adults esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with ge

USA - engelsk - NLM (National Library of Medicine)

advanced rx pharmacy of tennessee, llc - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - 1.1 healing of erosive esophagitis (ee) adults esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed ee in adults. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of esomeprazole magnesium delayed-release capsules may be considered. pediatric patients 12 years to 17 years of age esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) for the healing of ee in pediatric patients 12 years to 17 years of age. 1.2 maintenance of healing of ee esomeprazole magnesium delayed-release capsules are indicated for the maintenance of healing of ee in adults. controlled studies do not extend beyond 6 months. 1.3 treatment of symptomatic gerd adults esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with

USA - engelsk - NLM (National Library of Medicine)

eugia us llc - esomeprazole sodium (unii: l2c9gwq43h) (esomeprazole - unii:n3pa6559ft) - esomeprazole 20 mg - esomeprazole sodium for injection is indicated for the short-term treatment of gerd with ee in adults and pediatric patients 1 month to 17 years, inclusively as an alternative to oral therapy when oral esomeprazole is not possible or appropriate. esomeprazole sodium for injection is indicated for risk reduction of rebleeding of gastric or duodenal ulcers following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers in adults. - esomeprazole sodium for injection is contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation. hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see warnings and precautions (5.2), adverse reactions (6.2)]. - proton pump inhibitors (ppis), including esomeprazole sodium for injection, are contraindicated in patients receiving rilpivirine-containing products [see drug interactions (7)]. risk summary

Canada - engelsk - Health Canada

apotex inc - esomeprazole (esomeprazole magnesium) - tablet (delayed-release) - 20mg - esomeprazole (esomeprazole magnesium) 20mg - proton-pump inhibitors

Canada - engelsk - Health Canada

apotex inc - esomeprazole (esomeprazole magnesium) - tablet (delayed-release) - 40mg - esomeprazole (esomeprazole magnesium) 40mg - proton-pump inhibitors